Checklist for standardized reporting of drug-drug interaction management guidelines

Checklist for standardized reporting of drug-drug interaction management guidelines

Čájet eará veršuvnnaid (1)

Purpose: Inconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare provi...

Bibliográfalaš dieđut
Váldodahkkit:	Floor-Schreudering, A, Geerts, A, Aronson, J, Bouvy, M, Ferner, R, De Smet, P
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2014

Geahča maid

Checklist for standardized reporting of drug-drug interaction management guidelines.
Dahkki: Floor-Schreudering, A, et al.
Almmustuhtton: (2014)

Towards improved drug-drug interaction management guidelines
Dahkki: Floor-Schreudering, A, et al.
Almmustuhtton: (2013)

Pharmacogenetics and adverse drug reactions
Dahkki: Ferner, R, et al.
Almmustuhtton: (2010)

Clarification of terminology in drug safety.
Dahkki: Aronson, J, et al.
Almmustuhtton: (2005)

Communicating information about drug safety.
Dahkki: Ferner, R, et al.
Almmustuhtton: (2006)

Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.
Dahkki: Aronson, J, et al.
Almmustuhtton: (2010)

National differences in publishing papers on adverse drug reactions.
Dahkki: Ferner, R, et al.
Almmustuhtton: (2005)

EIDOS: a mechanistic classification of adverse drug effects.
Dahkki: Ferner, R, et al.
Almmustuhtton: (2010)

The toxicological significance of post-mortem drug concentrations in bile
Dahkki: Ferner, RE, et al.
Almmustuhtton: (2017)

Monitoring for the Adverse Effects of Drugs
Dahkki: Coleman, J, et al.
Almmustuhtton: (2008)

Joining the DoTS: new approach to classifying adverse drug reactions.
Dahkki: Aronson, J, et al.
Almmustuhtton: (2003)

Preventability of drug-related harms - part I: a systematic review.
Dahkki: Ferner, R, et al.
Almmustuhtton: (2010)

Defining rewardable innovation in drug therapy.
Dahkki: Aronson, J, et al.
Almmustuhtton: (2012)

A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy.
Dahkki: McDowell, SE, et al.
Almmustuhtton: (2013)

Nominal ISOMERs (Incorrect spellings of medicines eluding researchers)-variants in the spellings of drug names in PubMed: a database review
Dahkki: Ferner, R, et al.
Almmustuhtton: (2016)

Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: the effect of publicity
Dahkki: Ferner, RE, et al.
Almmustuhtton: (2022)

Serious drug interactions.
Dahkki: Aronson, J
Almmustuhtton: (1993)

Classifying drug interactions.
Dahkki: Aronson, J
Almmustuhtton: (2004)

Beneficial drug interactions.
Dahkki: Aronson, J
Almmustuhtton: (1994)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
Dahkki: Aronson, J
Almmustuhtton: (2008)

Designing and Psychometry of the Evaluation Checklist for the Registration and Labeling Guidelines of Anesthetic Drugs in the Operating Room
Dahkki: Parisa Moradimajd, et al.
Almmustuhtton: (2023-01-01)

Reporting guidelines for human microbiome research: the STORMS checklist
Dahkki: Mirzayi, C, et al.
Almmustuhtton: (2021)

Communicating information about drug interactions
Dahkki: Aronson, J
Almmustuhtton: (2007)

Interactions that matter: 10 Antiarrhythmic drugs
Dahkki: Aronson, J
Almmustuhtton: (1987)

Reporting guideline checklists are not quality evaluation forms: they are guidance for writing
Dahkki: Logullo, P, et al.
Almmustuhtton: (2020)

Meyler's side effects of drugs : the international encyclopedia of adverse drug reactions and interactions /
Dahkki: Aronson, Jeffrey K.
Almmustuhtton: (2006)

Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.
Dahkki: Aronson, J
Almmustuhtton: (2005)

The reporting checklist for public versions of guidelines: RIGHT-PVG
Dahkki: Xiaoqin Wang, et al.
Almmustuhtton: (2021-01-01)

RMJ research series – Using a Reporting Guideline (Checklist)
Dahkki: D. Hopkinson, et al.
Almmustuhtton: (2020-03-01)

Checking and correction of drug information in the standards of care and clinical guidelines
Dahkki: B. K. Romanov
Almmustuhtton: (2018-02-01)

Clinical pharmacology. Adverse drug interactions.
Dahkki: Aronson, J, et al.
Almmustuhtton: (1981)

Reporting Guidelines for Healthcare Guideline Adaptations: An Interpretation of the RIGHT-Ad@pt Checklist
Dahkki: GONG Liyun, et al.
Almmustuhtton: (2024-11-01)

Drug interactions-information, education, and the British National Formulary.
Dahkki: Aronson, J
Almmustuhtton: (2004)

Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore.
Dahkki: Hauben, M, et al.
Almmustuhtton: (2007)

STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
Dahkki: Jinghong Chen, et al.
Almmustuhtton: (2024-09-01)

The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM
Dahkki: Xuanlin Li, et al.
Almmustuhtton: (2024-01-01)

iCHECK-DH: Guidelines and Checklist for the Reporting on Digital Health Implementations
Dahkki: Caroline Perrin Franck, et al.
Almmustuhtton: (2023-05-01)

Guidelines of research biosimilar drugs
Dahkki: R. . Ivanov, et al.
Almmustuhtton: (2014-04-01)

Pharmacokinetic drug-drug interaction and their implication in clinical management
Dahkki: Palleria Caterina, et al.
Almmustuhtton: (2013-01-01)

Adverse drug reactions: definitions, diagnosis, and management.
Dahkki: Edwards, I, et al.
Almmustuhtton: (2000)